Immunomodulation does not alter histology in resected Crohn's disease

Area of Science:

• Gastroenterology and Hepatology
• Immunology
• Surgical Pathology

Background:

• Crohn's disease (CD) treatment increasingly involves immunomodulators (Azathioprine, 6-Mercaptopurine, Methotrexate) and biologics (Infliximab, adalimumab).
• These therapies aim to manage inflammation and alter the disease's natural progression.
• The study investigates the impact of pre-surgical immunomodulator or biologic use on disease histology.

Purpose of the Study:

• To determine if immunomodulator or biologic use in the two years prior to resection affects histopathological characteristics in Crohn's disease patients.
• To analyze the association between pre-surgical medication and histological findings, considering disease phenotype.

Main Methods:

• Retrospective review of 165 patients undergoing CD resection over a 10-year period (1996-2005).
• Analysis of clinical records and histology specimens.
• Patients receiving immunomodulators or biologics for over 3 months within 2 years of surgery were categorized; analysis included Montreal phenotype.

Main Results:

• 52 out of 165 patients received immunomodulators or biologics.
• No significant histological differences were observed in 20 examined features between treated and untreated groups.
• Muscular hypertrophy approached statistical significance (P=0.05).
• Patients with stricturing disease (Montreal B phenotype) were significantly more likely to have received immunomodulators (P=0.03).

Conclusions:

• Patients requiring resection for stricturing Crohn's disease are more likely to have received immunomodulators or biologics.
• Pre-surgical use of these medications did not lead to significant histological differences in resected specimens.
• The findings suggest that while these drugs are used more in complex disease, they do not alter the fundamental histology of the resected tissue.